Hydroxychloroquine in Patients with Rheumatic Disease Complicated by COVID-19: Clarifying Target Exposures and the Need for Clinical Trials
Stephen J. Balevic(Duke University), Michael Cohen‐Wolkowiez(Duke University), Brenna L. Hughes(Brown University), Amanda M. Eudy(Duke University), Daniel González(University of North Carolina at Chapel Hill), Christoph P. Hornik(Duke University), Megan E. B. Clowse(Duke University), Geeta K. Swamy(Unknown), Thomas P. Green(Duke University), Anil R. Maharaj(Clinical Research Institute), Laura E. Schanberg(Duke University)
Cited by 21
Related Papers
Significance of Protein Binding in Pharmacokinetics and Pharmacodynamics
|Journal of Pharmaceutical Sciences|2009|337
A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study)
|Clinical Infectious Diseases|2020|232
Dexamethasone reduces the inflammatory response to cardiopulmonary bypass in children
|The Annals of Thoracic Surgery|2000|224
Selection of Antiobesity Medications Based on Phenotypes Enhances Weight Loss: A Pragmatic Trial in an Obesity Clinic
|Obesity|2021|199
Noninvasive positive-pressure ventilation in children with lower airway obstruction*
|Pediatric Critical Care Medicine|2004|170